Abstracts tagged "glucocorticoids"

Abstract Number: 1598 • ACR Convergence 2024
Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis Using Simulation Modeling
Naomi Patel¹, Aaron Wu¹, Shruthi Srivatsan¹, Eli Miloslavsky², Peter Merkel³, John Stone⁴, Hyon K. Choi⁵, Emily Hyle¹ and Zachary Wallace², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA, ³University of Pennsylvania, Philadelphia, PA, ⁴Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁵Massachusetts General Hospital, Lexington, MA
Background/Purpose: Glucocorticoids (GCs) remain a cornerstone of treatment of ANCA-associated vasculitis (AAV) but predispose people to infectious, metabolic, and other toxicities. We projected the long-term…
Abstract Number: 2273 • ACR Convergence 2024
Time-Trends in Real-World Glucocorticoid Treatment Strategies in Patients with Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort(CATCH) Study
Orit Schieir¹, Marie-France Valois², Louis Bessette³, Carter Thorne⁴, Gilles Boire⁵, Susan Bartlett², Glen Hazlewood⁶, Carol Hitchon⁷, Diane Tin⁴, Hugues Allard-Chamard⁸, Bindee Kuriya⁹, Janet Pope¹⁰ and Vivian Bykerk¹¹, and on behalf of CATCH Investigators., ¹McGill University, Montreal, QC, Canada, ²Centre for Outcomes Research & Eval, Montreal, QC, Canada, ³University of Laval, Quebec City, QC, Canada, ⁴Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ⁵Retired, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸University of Sherbrooke, Sherbrooke, QC, Canada, ⁹University of Toronto, Toronto, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Hospital For Special Surgery, New York, NY
Background/Purpose: Increased availability of a wider array of effective RA treatments and evidence of glucocorticoid (GC)-related adverse events have prompted updated recommendations limiting GC use…
Abstract Number: 2528 • ACR Convergence 2024
Activation of the Hes1/Piezo1 Pathway Promotes Mechanical Stress Response and Prevents Glucocorticoid-induced Osteoporosis
Nagahiro Ochiai¹, Yuki Etani², Takaaki Noguchi², Taihei Miura², Takuya Kurihara², Yuji Fukuda², Hidetoshi Hamada², Keisuke Uemura², Kazuma Takashima², Masashi Tamaki², Teruya Ishibashi², Shohei Ito³, Satoshi Yamakawa², Takashi Kanamoto², Seiji Okada², Ken Nakata² and Kosuke Ebina², ¹Taisho Pharmaceutical Co., Ltd., Saitama, Saitama, Japan, ²Osaka University, Suita, Japan, ³Taisho Pharmaceutical, Co., Ltd., Saitama, Japan
Background/Purpose: This study investigated the diminished expression of Piezo1 (Piezo-type mechanosensitive ion channel component 1), a mechanosensitive receptor, in bone tissues of both patients and…
Abstract Number: 0769 • ACR Convergence 2024
Baseline Evaluation of Diagnoses and Prescribing Patterns in Polymyalgia Rheumatica
Laura Stradford¹, Shilpa Venkatachalam², Kelly Gavigan³, Angela Degrassi³, Emily Holladay⁴, Fenglong xie⁵, Yujie Su⁶, Shanette Daigle⁷ and Jeffrey Curtis⁸, ¹Global Healthy Living Foundation, Nyack, NY, ²Global Healthy Living Foundation, New York, NY, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham; Illumination Health, Birmingham, AL, ⁶Illumination Health, Hoover, AL, ⁷FASTER, Birmingham, AL, ⁸University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Polymyalgia rheumatica (PMR) is a chronic inflammatory rheumatic condition that affects approximately 800,000 people in the U.S., occurring almost exclusively after age 50. Moreover,…
Abstract Number: 1616 • ACR Convergence 2024
Vitamin D Supplementation in the Prevention of Severe Adverse Effects Caused ByGlucocorticoids: Study from the ARTESER Registry of Giant Cell Arteritis
Gaston Ariel Ghio¹, Marta Domínguez-Álvaro², Ricardo Blanco-Alonso³, Santos Castañeda⁴, Iñigo Hernández-Rodríguez⁵, Elisa Fernández-Fernández:⁶, Maite Silva-Diaz⁷, Joaquin María Belzunegui:⁸, Clara Moriano⁹, Julio Sánchez-Martín¹⁰, Javier Narvaez-García¹¹, Eva Galindez¹², Anne Riveros Frutos¹³, Francisco Ortiz Sanjuán¹⁴, Tarek Carlos Salman Monte:¹⁵, Margarida Vasques Rocha:¹⁶, Carlota L Iñiguez:¹⁷, Alicia García Dorta¹⁸, Clara Molina Almela¹⁹ and María Alcalde Villar:²⁰, and ARTESER Project Collaborative Group, ¹Hospital Universitari Mutua Terrassa, Terrassa, Catalonia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁶La Paz University Hospital, Alcalá de Henares, Madrid, Spain, ⁷Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁸H de Donostia, Donostia-San Sebasti, Spain, ⁹Hospital León, LEON, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹²Hospital Universitario de Cabueñes, Bilbao, Spain, ¹³Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹⁴Hospital Universitario de Cabueñes, Gijón, Asturias, Spain, ¹⁵Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹⁶Hospital Universitario Araba, Vitoria, Spain, ¹⁷Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, ¹⁸Rheumatologist, La Laguna, Spain, ¹⁹Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ²⁰Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain
Background/Purpose: Glucocorticoids (GC) are the gold standard for the treatment of giant cellarteritis (GCA). However, these drugs, when used at high doses and for prolonged…
Abstract Number: 2279 • ACR Convergence 2024
Discontinuation Pattern of Glucocorticoids in Patients with Rheumatoid Arthritis Initiating Biologics or Targeted Synthetic DMARDs in Routine Care
Isabel Castrejon¹, Lucia Otero-Varela², José María Álvaro-Gracia³, Jerusalem Calvo Gutierrez⁴, Cristina Campos-Fernández⁵, Alicia García Dorta⁶, Ana Perez⁷, DOLORES RUIZ MONTESINO⁸ and Fernando Sánchez-Alonso⁹, and on behalf of BIOBADASER, ¹Hospital General Universitario Gregorio Marañon, Madrid, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Hospital Gregorio Marañón, Madrid, Spain, ⁴HU Reina Sofia, Cordoba, Spain, ⁵Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ⁶Rheumatologist, La Laguna, Spain, ⁷Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, ⁸Hospital Virgen Macarena, Sevilla, Spain, ⁹Sociedad Española de Reumatología, Madrid, Spain
Background/Purpose: Glucocorticoids (GC) have a rapid effect on symptoms, but chronic exposure is associated to important adverse events. Although both EULAR and ACR guidelines (1,2),…
Abstract Number: 2567 • ACR Convergence 2024
Gene Expression in Osteonecrosis of the Femoral Head: A Region-matched RNA-sequencing Study
Lucy Eunju Lee¹, Seung Hwan Lee², Miri Kim², Jieun Kim², Joo Sung Shim², Eun Gyel Shin², Tae Sung Lee², Hyuck Min Kwon², Young Han Lee², Hun-Mu Yang², Kwan Kyu Park² and Jason Jungsik Song², ¹Yonsei University, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Osteonecrosis of the femoral head (ONFH) is linked to diverse risk factors like glucocorticoid use and excessive alcohol consumption. Various cells may influence bone…
Abstract Number: 0770 • ACR Convergence 2024
Efficacy and Safety of Upadacitinib in Patients with Giant Cell Arteritis (SELECT-GCA): A Double-Blind, Randomized Controlled Phase 3 Trial
Peter Merkel¹, Sara Penn², Arathi Setty², Wolfgang Schmidt³, Andrea Rubbert-Roth⁴, Ellen Margrethe Hauge⁵, Helen Keen⁶, Tomonori Ishii⁷, Nader Khalidi⁸, Liu Meng², weihan zhao², Ivan Lagunes⁹, Ana B. Romero², Peter Wung¹⁰ and daniel blockmans¹¹, ¹Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²AbbVie, North Chicago, IL, ³Immanuel Krankenhaus Berlin, Berlin, Germany, ⁴Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁵Aarhus Universitetshospital, Aarhus, Denmark, ⁶University of Western Australia, Daglish, Western Australia, Australia, ⁷Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, sendai, Japan, ⁸McMaster University, Hamilton, ON, Canada, ⁹Abbvie, Inc, North Chicago, IL, ¹⁰AbbVie Inc., North Chicago, IL, ¹¹Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium; Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: The objective was to assess the efficacy and safety of UPA vs placebo (PBO), in combination with a GC taper regimen, in patients with…
Abstract Number: 1646 • ACR Convergence 2024
A Novel E3 Ligase of GILZ: Validation of a Steroid-sparing Therapeutic Target in SLE
Iolanda Miceli¹, Rochelle Sherlock², Pamela Hall², IanIan Cheang², Akshay D'Cruz³, Taylah Bennett², Terry Lim Kam Sian², Rangi Kandane-Rathnayake⁴, Eric Morand⁵ and Sarah Jones², ¹Monash University, Glen Iris, Victoria, Australia, ²Monash University, Melbourne, Australia, ³Monash University, Me, Australia, ⁴Monash University, Clayton, Victoria, Australia, ⁵School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: SLE is primarily mediated by B cell dysregulation on a background of type I interferon (IFN) activation. This multi-faceted nature of immune defects in…
Abstract Number: 2372 • ACR Convergence 2024
Incidence and Predictors of Recurrent Pericarditis in Systemic Lupus Erythematosus
Yoo Jin Kim¹, Jana Lovell¹, Alaa Diab¹, Laurence Magder², Daniel Goldman³, Michelle Petri³, Luigi Adamo¹ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²University of Maryland, Baltimore, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Pericarditis is the most common cardiac manifestation of systemic lupus erythematosus (SLE). In the general population, pericarditis commonly recurs (~30%), likely due to immune-mediated…
Abstract Number: 2606 • ACR Convergence 2024
Changes in Long-term GC Use Among Older Adults After New Diagnosis of Late-onset Rheumatoid Arthritis
Jiha Lee¹, Jonathan Martindale¹, Beth Wallace², Namrata Singh³, Una Makris⁴ and Julie Bynum¹, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³University of Washington, Bellevue, WA, ⁴UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Older adults with late-onset rheumatoid arthritis (LORA) receive less disease-modifying anti-rheumatic drugs (DMARDs), which is the standard of care. In contrast, long-term glucocorticoid (GC)…
Abstract Number: 0774 • ACR Convergence 2024
A Multicenter, Randomized, Controlled Trial to Evaluate the Effects of Low-dose Glucocorticoids Compared to Stopping Glucocorticoids to Maintain Remission of Granulomatosis with Polyangiitis: The TAPIR Trial
Peter Merkel¹, Christian Pagnoux², Nader Khalidi³, Ulrich Specks⁴, Curry Koening⁵, Carol Langford⁶, Larry Moreland⁷, Paul Monach⁸, Jason Springer⁹, Shubhasree Banerjee¹, Simon Carette¹⁰, Rennie Rhee¹, Medha Soowamber¹¹, Kenneth Warrington⁴, Renee Borchin¹², Cristina Burroughs¹³, Carol McAlear¹, David Cuthbertson¹³ and Jeffrey Krischer¹³, ¹University of Pennsylvania, Philadelphia, PA, ²Mount Sinai Hospital, Toronto, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Mayo Clinic, Rochester, MN, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Colorado, Denver, CO, ⁸VA Boston Healthcare System, Boston, MA, ⁹Vanderbilt University Medical Center, Franklin, TN, ¹⁰Mount Sinai Hosptial, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²University of South Florida, Tampa, ¹³University of South Florida, Tampa, FL
Background/Purpose: Use of low-dose glucocorticoids to maintain remission in patients with granulomatosis with polyangiitis (GPA) remains controversial. Additionally, there is no consensus on how to…
Abstract Number: 1695 • ACR Convergence 2024
Efficacy of Upadacitinib in Patients with Giant Cell Arteritis: Subgroup Analysis of the SELECT-GCA Phase 3 Trial
Peter Merkel¹, Arathi Setty², Ricardo Blanco-Alonso³, Ravi Suppiah⁴, Thomas Daikeler⁵, Valerie Devauchelle⁶, Elisabeth Brouwer⁷, Hiromichi Tamaki⁸, Liu Meng², Yang Yang², Avani Joshi², Charles Phillips², Peter K. Wung² and Cristina Ponte⁹, ¹Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²AbbVie, North Chicago, IL, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁴Health New Zealand, Te Toka Tumai Auckland, Auckland, New Zealand, ⁵university hospital, Basel, Switzerland, ⁶UBO, Brest, France, ⁷University Medical Center Groningen, Groningen, Netherlands, ⁸St. Luke's International Hospital, Tokyo, Japan, ⁹Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal., Lisbon, Portugal
Background/Purpose: Giant cell arteritis (GCA) is a chronic systemic vasculitis with limited targeted therapeutic options. The recent SELECT-GCA phase 3 trial demonstrated a favorable benefit-risk…
Abstract Number: 2419 • ACR Convergence 2024
Clinical and Patient-reported Outcomes in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS) US Data
Richard Furie¹, Mawuena Binka², Gelareh Atefi³, Stephanie Y. Chen⁴ and Bo Ding⁵, ¹Northwell Health, Manhasset, NY, ²BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ³AstraZeneca, Media, PA, ⁴BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: SLE is an autoimmune disease with diverse manifestations and progression patterns that, via disease activity and effects of standard therapy, imposes a significant burden…
Abstract Number: 2648 • ACR Convergence 2024
Diagnosis of Giant Cell Arteritis by 18F-FDG PET/CT in Patients on Glucocorticoid Therapy: Importance of Delayed Imaging
Vicente Aldasoro¹, Vicky Betech-Antar², Santos Castañeda³, Eugenio De Miguel⁴, Juan José Rosales⁵ and Maria Jose García Velloso⁵, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Clinica Universidad de Navarra, Pamplona, Spain, ³Hospital Universitario de la Princesa, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Clínica Universidad de Navarra, Pamplona, Spain
Background/Purpose: The aim of this study is to analyse the diagnostic value of the delay images at 180 minutes in positron emission tomography (PET) performed in…

« Previous Page
1
…
5
6
7
8
9
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].